ATE410183T1 - Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden - Google Patents

Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden

Info

Publication number
ATE410183T1
ATE410183T1 AT99968288T AT99968288T ATE410183T1 AT E410183 T1 ATE410183 T1 AT E410183T1 AT 99968288 T AT99968288 T AT 99968288T AT 99968288 T AT99968288 T AT 99968288T AT E410183 T1 ATE410183 T1 AT E410183T1
Authority
AT
Austria
Prior art keywords
related methods
adjuvant compositions
based adjuvant
adjuvant
animal
Prior art date
Application number
AT99968288T
Other languages
English (en)
Inventor
John Walker
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE410183T1 publication Critical patent/ATE410183T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
AT99968288T 1999-01-08 1999-12-24 Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden ATE410183T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8073A AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE410183T1 true ATE410183T1 (de) 2008-10-15

Family

ID=3812278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968288T ATE410183T1 (de) 1999-01-08 1999-12-24 Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden

Country Status (15)

Country Link
US (2) US9579379B1 (de)
EP (2) EP1946773A3 (de)
JP (2) JP4949555B2 (de)
AT (1) ATE410183T1 (de)
AU (2) AUPP807399A0 (de)
CA (2) CA2359111C (de)
CY (1) CY1108693T1 (de)
DE (1) DE69939706D1 (de)
DK (1) DK1140165T3 (de)
ES (1) ES2317708T3 (de)
NZ (1) NZ512011A (de)
PT (1) PT1140165E (de)
TW (1) TW533079B (de)
WO (1) WO2000041720A1 (de)
ZA (1) ZA200105543B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
CA2572427A1 (en) * 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
BRPI0611390A2 (pt) * 2005-06-01 2010-09-08 Pfizer Prod Inc composições de vacina e uso de composições compreendendo vacina anti-lhrh na preparação de um medicamento para tratar incontinência urinária
WO2008110912A1 (en) * 2007-03-14 2008-09-18 Pfizer Inc. Fertility regulation in horses
MX337723B (es) 2008-12-09 2016-03-15 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
DK2473605T3 (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
SG181628A1 (en) 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
ES2639122T3 (es) 2011-05-13 2017-10-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EP2659907A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659906A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
RU2666141C2 (ru) 2013-09-17 2018-09-06 Оби Фарма, Инк. Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
UA121200C2 (uk) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
KR20160077214A (ko) 2013-12-16 2016-07-01 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
EP3107567A4 (de) 2014-02-19 2017-10-25 Cangene Corporation Verfahren zur modulierung einer immunreaktion
CA3104268A1 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
EP3244917B1 (de) 2015-01-15 2023-04-19 Pfizer Inc. Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
EP4248992A3 (de) * 2015-01-16 2023-12-27 Zoetis Services LLC Impfstoffs gegen maul- und klauenseuche
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
EP3319988A1 (de) 2015-07-07 2018-05-16 Affiris AG Impfstoffe zur behandlung und prävention von ige-vermittelten krankheiten
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
HUE056769T2 (hu) 2015-09-04 2022-03-28 Primatope Therapeutics Inc Humanizált anti-CD40 antitestek és felhasználásuk
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (de) 2016-07-29 2020-07-29 OBI Pharma, Inc. Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3849521A1 (de) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanopartikelimpfstoffadjuvanz und verfahren zur verwendung davon
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
CN113967252B (zh) * 2020-07-24 2024-03-26 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4237428A2 (de) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli zusammensetzungen und verfahren dafür
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US20240299510A1 (en) 2020-12-31 2024-09-12 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
US20250161429A1 (en) 2022-02-14 2025-05-22 University Of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof
AU2024296166A1 (en) * 2023-07-07 2025-09-25 Ouro Fino Saúde Animal Ltda Modified gnrh peptide and its conjugate for mammalian immunocastration, manufacturing method, composition and kit
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1924304C3 (de) * 1969-05-13 1980-07-17 Bayer Ag, 5090 Leverkusen Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren
DE3411224A1 (de) 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
WO1988005308A1 (en) * 1987-01-14 1988-07-28 Commonwealth Scientific And Industrial Research Or Anti reproductive hormone
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
US4892830A (en) * 1987-04-02 1990-01-09 Baylor College Of Medicine Environmentally controlled in vitro incubator
GB2228262B (en) 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU5186090A (en) 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
NZ235038A (en) * 1989-08-25 1992-09-25 Biotech Australia Pty Ltd Outermembrane lipoprotein (tratp)/lhrh fusion protein and its use in immunological castration or reproductive inhibition
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1997015316A1 (en) 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
AUPP060097A0 (en) * 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response

Also Published As

Publication number Publication date
CA2359111A1 (en) 2000-07-20
EP1140165B1 (de) 2008-10-08
TW533079B (en) 2003-05-21
ES2317708T3 (es) 2009-04-16
US9149520B2 (en) 2015-10-06
CY1108693T1 (el) 2012-05-23
JP2012072157A (ja) 2012-04-12
JP4949555B2 (ja) 2012-06-13
PT1140165E (pt) 2009-01-13
EP1140165A4 (de) 2005-01-05
EP1946773A3 (de) 2008-07-30
NZ512011A (en) 2002-12-20
WO2000041720A8 (en) 2000-11-09
AUPP807399A0 (en) 1999-02-04
US20120251566A1 (en) 2012-10-04
AU2526300A (en) 2000-08-01
WO2000041720A1 (en) 2000-07-20
CA2660344A1 (en) 2000-07-20
DE69939706D1 (de) 2008-11-20
AU758133B2 (en) 2003-03-13
DK1140165T3 (da) 2009-02-16
ZA200105543B (en) 2003-01-22
EP1140165A1 (de) 2001-10-10
JP2002534480A (ja) 2002-10-15
US9579379B1 (en) 2017-02-28
CA2359111C (en) 2014-02-18
EP1946773A2 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
DE69939706D1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
ATE229978T1 (de) Helicobacter proteine und impstoffe
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
EP1326633A4 (de) Zusammensetzung mit immunogenen mikroteilchen
DK0764029T3 (da) Proteinadjuvanser
DK55891A (da) Matrix med immunomodulerende virkning
CA2217178A1 (en) Vaccines containing a saponin and a sterol
ZA936629B (en) Potentiation of immunogenic response
NO991524L (no) Vaksiner
AU7814498A (en) Multivalent (in ovo) avian vaccine
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
NO972219D0 (no) Immunogenpreparater
NL300183I1 (nl) Acellulair vaccin.
BR9815404A (pt) Composição adjuvante para estimular uma eficiente resposta imunológica a uma substância antigênica, vacina para administração a um animal, processo para estimular uma resposta imunológica eficaz em um animal a uma substância antigênica, e, uso da composição adjuvante.
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
SE9600646D0 (sv) Vaccin
MX9700215A (es) Proteinas y vacunas de helicobacter.
MX9710523A (es) Vacunas contra hepatitis c.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140165

Country of ref document: EP